DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc.

$8.23

-0.12 -1.44% today

Price History

Not enough data

Key Stats

Market Cap

443.81M

Avg Volume

181,775

EPS

-$0.71

52W High

$10.42

52W Low

$5.25

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-10.19

P/B Ratio

11.58

EV/EBITDA

-10.22

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(114.6%)

Return on Assets

(64.1%)

Liquidity & Leverage

Current Ratio

6.72

Quick Ratio

6.63

Debt / Equity

0.00

Total Cash

43.50M

Total Debt

185,000

About

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.